Aadi Bioscience, Inc.

NasdaqCM AADI

Aadi Bioscience, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024

Aadi Bioscience, Inc. Capital Expenditure is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Aadi Bioscience, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -3.23 M, a -684.95% change year over year.
Aadi Bioscience, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -412.00 K.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqCM: AADI

Aadi Bioscience, Inc.

CEO	Mr. David J. Lennon Ph.D.
IPO Date	Feb. 16, 2018
Location	United States
Headquarters	17383 Sunset Boulevard
Employees	53
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Key trends

Past 5 years